Gen-X will execute a project for Arthrogen B.V. to screen for new promoter candidates
Gen-X will execute a project for Arthrogen B.V. to identify gene regulatory elements for Arthrogen’s gene therapy strategy. The project leverages the SuRE technology to screen the entire human genome for promoters and enhancers that will benefit Arthrogen’s vector development platform.
Arthrogen, an Amsterdam based biopharmaceutical company, is developing local gene therapy, using viral mediated gene transfer. The first target indication is in the field of rheumatic diseases.